131 related articles for article (PubMed ID: 11249642)
1. Technology evaluation: transgenic alpha-1-antitrypsin (AAT), PPL therapeutics.
Tebbutt SJ
Curr Opin Mol Ther; 2000 Apr; 2(2):199-204. PubMed ID: 11249642
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
[TBL] [Abstract][Full Text] [Related]
3. Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.
McElvaney NG
Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S191-6. PubMed ID: 27115956
[TBL] [Abstract][Full Text] [Related]
4. Biotechnology. Sheep fail to produce golden fleece.
Vogel G
Science; 2003 Jun; 300(5628):2015-6. PubMed ID: 12829753
[No Abstract] [Full Text] [Related]
5. Production of therapeutic proteins in the milk of transgenic livestock.
Colman A
Biochem Soc Symp; 1998; 63():141-7. PubMed ID: 9513718
[TBL] [Abstract][Full Text] [Related]
6. Antibody response to aerosolized transgenic human alpha1-antitrypsin.
Spencer LT; Humphries JE; Brantly ML;
N Engl J Med; 2005 May; 352(19):2030-1. PubMed ID: 15888711
[No Abstract] [Full Text] [Related]
7. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency.
Tirado-Conde G; Lara B; Miravitlles M
Ther Adv Respir Dis; 2008 Feb; 2(1):13-21. PubMed ID: 19124355
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector.
Lu Y; Choi YK; Campbell-Thompson M; Li C; Tang Q; Crawford JM; Flotte TR; Song S
J Gene Med; 2006 Jun; 8(6):730-5. PubMed ID: 16518879
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy progress and prospects: alpha-1 antitrypsin.
Stecenko AA; Brigham KL
Gene Ther; 2003 Jan; 10(2):95-9. PubMed ID: 12571637
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use.
Karnaukhova E; Ophir Y; Golding B
Amino Acids; 2006 Jun; 30(4):317-32. PubMed ID: 16773239
[TBL] [Abstract][Full Text] [Related]
11. Prolastin aerosol therapy and sputum taurine in cystic fibrosis.
Cantin AM; Berthiaume Y; Cloutier D; Martel M
Clin Invest Med; 2006 Aug; 29(4):201-7. PubMed ID: 16986483
[TBL] [Abstract][Full Text] [Related]
12. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
13. Alpha 1-antitrypsin augmentation therapy.
Sandhaus RA
Agents Actions Suppl; 1993; 42():97-102. PubMed ID: 8356934
[TBL] [Abstract][Full Text] [Related]
14. Delivery of Alpha-1 Antitrypsin to Airways.
Griese M; Scheuch G
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S346-51. PubMed ID: 27564672
[TBL] [Abstract][Full Text] [Related]
15. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency.
Louie SG; Sclar DA; Gill MA
Ann Pharmacother; 2005 Nov; 39(11):1861-9. PubMed ID: 16219903
[TBL] [Abstract][Full Text] [Related]
16. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis.
McElvaney NG; Hubbard RC; Birrer P; Chernick MS; Caplan DB; Frank MM; Crystal RG
Lancet; 1991 Feb; 337(8738):392-4. PubMed ID: 1671425
[TBL] [Abstract][Full Text] [Related]
17. Revisiting alpha1-antitrypsin therapy in cystic fibrosis: can it still offer promise?
Brennan S
Eur Respir J; 2007 Feb; 29(2):229-30. PubMed ID: 17264320
[No Abstract] [Full Text] [Related]
18. Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future.
Oermann CM
Curr Opin Investig Drugs; 2001 Jul; 2(7):900-6. PubMed ID: 11757788
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: cystic fibrosis therapy, Genzyme.
Cockett MI
Curr Opin Mol Ther; 1999 Apr; 1(2):279-83. PubMed ID: 11715952
[TBL] [Abstract][Full Text] [Related]
20. Association of improved pulmonary phenotype in Irish cystic fibrosis patients with a 3' enhancer polymorphism in alpha-1-antitrypsin.
Courtney JM; Plant BJ; Morgan K; Rendall J; Gallagher C; Ennis M; Kalsheker N; Elborn S; O'Connor CM
Pediatr Pulmonol; 2006 Jun; 41(6):584-91. PubMed ID: 16617455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
